Quetiapine Fumarate Market Size, Share, Growth, and Industry Analysis, By Types (Immediate Release Tablets, Extended Release Tablets, Others), By Applications Covered (Schizophrenia, Bipolar Disorder, Depression, Others), Regional Insights and Forecast to 2033

Quetiapine Fumarate Market Size

The Quetiapine Fumarate market size was valued at USD 151.44 million in 2024 and is expected to decrease slightly to USD 149.93 million in 2025, reaching USD 138.34 million by 2033, reflecting a decline of -1.0% during the forecast period from 2025 to 2033.

The US Quetiapine Fumarate market accounted for approximately 40% of the global market share in 2022. The demand is driven by increasing mental health disorder diagnoses and growing access to affordable generic versions.

The Quetiapine Fumarate market is growing, driven by the increasing prevalence of mental health disorders such as schizophrenia, bipolar disorder, and major depressive disorder. In 2023, the market was valued at approximately 4.5% of the global antipsychotic medication market and is expected to reach around 6.8% by 2032. The expiration of the original Seroquel patent has led to the rise of affordable generic versions, making the medication more accessible. This trend has significantly contributed to the market's growth. Additionally, advancements in drug formulations and delivery methods are expected to boost the adoption of Quetiapine Fumarate, expanding its use across diverse therapeutic applications.

Quetiapine Fumarate Market Trends

The Quetiapine Fumarate market is experiencing key growth trends. In 2022, the market share for Quetiapine Fumarate accounted for approximately 4.5%, with significant growth expected in the coming years. This growth is driven by the rising acceptance of pharmacological treatments for mental health disorders. As awareness of mental health issues increases, more individuals seek professional help, fueling the demand for medications like Quetiapine Fumarate. Additionally, the expiration of the Seroquel patent and the subsequent availability of generic versions have led to increased accessibility, driving demand. The entry of generic competitors has made Quetiapine Fumarate more affordable, expanding its use across diverse patient populations. Furthermore, ongoing research into new therapeutic applications of Quetiapine Fumarate is expected to broaden its market potential, contributing to continued growth.

Quetiapine Fumarate Market Dynamics

The dynamics of the Quetiapine Fumarate market are influenced by several factors. The increasing prevalence of mental health disorders such as schizophrenia, bipolar disorder, and major depressive disorder is a significant driver, with approximately 6.5% of the global population affected by these conditions. As awareness of these disorders grows, more patients seek treatment, contributing to market expansion. The growing acceptance of antipsychotic medications as part of a comprehensive treatment plan has been crucial for market growth. Additionally, the expiration of the original Seroquel patent and the entry of generic versions have made Quetiapine Fumarate more affordable, leading to broader accessibility and further market penetration. Ongoing research into alternative drug formulations and potential new therapeutic applications is expected to continue driving the demand for Quetiapine Fumarate in the coming years.

Drivers of Market Growth

" Increasing prevalence of mental health disorders"

The Quetiapine Fumarate market is driven by the growing global burden of mental health conditions. Schizophrenia, bipolar disorder, and major depressive disorder affect approximately 6.5% of the global population, with these figures rising annually. As awareness of mental health issues increases, more individuals are seeking professional help, thus driving demand for effective treatments like Quetiapine Fumarate. Additionally, the increasing acceptance of pharmacological treatments for mental health conditions is expanding the market for antipsychotic medications. The availability of more affordable generic versions following the expiration of Seroquel’s patent has also enhanced accessibility, further fueling market growth.

Market Restraints

" Side effects and regulatory concerns"

Despite the growing demand for Quetiapine Fumarate, there are several restraints limiting market growth. The medication’s potential side effects, including sedation, weight gain, and metabolic issues, can deter patients from consistent use. Regulatory concerns over the long-term safety of antipsychotic medications also limit the widespread adoption of Quetiapine Fumarate in some regions. These factors contribute to patient hesitancy, which has an impact on market penetration. Additionally, physicians may opt for other treatments based on the side effect profile of Quetiapine Fumarate, creating a competitive environment for alternative antipsychotic medications.

Market Opportunities

"Expanding access to mental health treatments"

The Quetiapine Fumarate market holds significant opportunities in the expansion of mental health treatment access globally. With increasing awareness of mental health disorders, more patients are seeking pharmacological solutions. This has led to higher demand for antipsychotic medications, particularly in developing regions where access to mental health treatments is limited. The availability of affordable generic versions of Quetiapine Fumarate has made it a viable treatment option for a broader patient base. Additionally, ongoing research into the development of new formulations or delivery methods could increase patient adherence and expand the market’s reach across different demographic groups.

Market Challenges

" Competition from alternative treatments"

One of the key challenges facing the Quetiapine Fumarate market is the intense competition from alternative antipsychotic medications. The market is flooded with both branded and generic options, which increases the difficulty for Quetiapine Fumarate to maintain its position as a first-line treatment. Many other atypical antipsychotics offer similar therapeutic benefits but may have a different side effect profile, making them more appealing to patients and healthcare providers. This competition has led to market fragmentation, where newer drugs may pose a challenge to the continued growth and market share of Quetiapine Fumarate.

Segmentation Analysis

The Quetiapine Fumarate market is segmented by type and application. By type, it includes Immediate Release Tablets, Extended Release Tablets, and Other formulations. The market applications are based on the primary mental health conditions treated with Quetiapine Fumarate, including schizophrenia, bipolar disorder, depression, and other related disorders. These segments are crucial in identifying growth opportunities in different therapeutic areas, as well as understanding how different formulations are utilized in treating various conditions. The demand for different types and applications will vary based on patient needs, treatment guidelines, and market dynamics in different regions.

By Type:

• Immediate Release Tablets: Immediate Release Tablets of Quetiapine Fumarate are designed for quick absorption into the bloodstream. This type of tablet accounted for approximately 55% of the market in 2022, primarily due to its fast onset of action, making it suitable for patients requiring immediate relief from symptoms. Immediate release tablets are commonly prescribed for acute episodes of schizophrenia and bipolar disorder, where quick therapeutic effects are crucial. The widespread adoption of this formulation is driven by its ability to provide rapid symptom control, enhancing patient adherence and satisfaction. This demand is expected to remain high, particularly for acute treatment regimens.

•  Extended Release Tablets: Extended Release Tablets of Quetiapine Fumarate, which provide a gradual release of the medication over time, accounted for around 32% of the market in 2022. These tablets are preferred for long-term management of conditions such as bipolar disorder and schizophrenia, where consistent therapeutic levels are needed to maintain symptom control. The growing focus on improving patient compliance and reducing the risk of side effects has driven the adoption of extended-release formulations. As these tablets help minimize fluctuations in drug concentrations, they are increasingly favored in maintenance treatments, leading to continued growth in this segment.

•  Others: Other formulations of Quetiapine Fumarate, such as liquid forms and combination therapies, represent approximately 13% of the market. These alternative forms are designed for patients who have difficulty swallowing tablets or require customized dosages. Liquid forms are particularly useful in pediatric and geriatric populations, where ease of administration is essential. Although smaller in market share, the demand for these formulations is steadily increasing as healthcare providers aim to accommodate a wider range of patient needs. This segment is expected to see growth as new dosage forms are introduced to meet diverse patient preferences.

By Application:

• Schizophrenia: Schizophrenia is one of the largest application segments for Quetiapine Fumarate, representing around 40% of the market in 2022. Quetiapine Fumarate is commonly prescribed for managing symptoms of schizophrenia, such as delusions, hallucinations, and cognitive impairments. The increasing global prevalence of schizophrenia, with about 1% of the population affected, continues to drive the demand for effective antipsychotic treatments. The effectiveness of Quetiapine in treating both acute and long-term symptoms of schizophrenia makes it a preferred choice for healthcare providers, further contributing to its dominant market share in this therapeutic area.

• Bipolar Disorder: Bipolar disorder is another major application for Quetiapine Fumarate, accounting for approximately 35% of the market in 2022. Quetiapine is commonly used for both manic and depressive episodes associated with bipolar disorder. The global rise in the diagnosis of bipolar disorder, driven by increasing awareness and improved diagnostic practices, is fueling market growth. As a preferred treatment for managing mood swings and preventing relapse, Quetiapine Fumarate is widely used in the long-term management of bipolar disorder. This segment is expected to continue growing as treatment options for bipolar disorder evolve and improve.

• Depression: Depression represents around 15% of the market for Quetiapine Fumarate, where it is often prescribed as an adjunctive treatment to antidepressants for patients who have not responded well to monotherapy. Quetiapine's ability to help manage depressive symptoms in patients with major depressive disorder (MDD) or treatment-resistant depression has increased its use in this application. With approximately 5% of the global population affected by depression, the demand for effective treatments like Quetiapine continues to rise. This segment is anticipated to grow as more patients are diagnosed and seek combination therapies to better manage their condition.

Quetiapine Fumarate Regional Outlook

The Quetiapine Fumarate market is showing varied growth across regions. North America leads the global market, driven by a high prevalence of mental health disorders and an established healthcare infrastructure. Europe follows closely, with significant demand for Quetiapine Fumarate in the treatment of bipolar disorder and schizophrenia. Asia-Pacific is experiencing rapid growth due to the increasing recognition of mental health conditions and improved access to treatment. In the Middle East & Africa, market growth is slower but is expected to pick up due to rising awareness and improved healthcare systems.

North America

North America holds a dominant share of the Quetiapine Fumarate market, accounting for approximately 45% in 2022. The high prevalence of mental health disorders in the region, combined with well-established healthcare infrastructure, has led to significant demand for antipsychotic medications like Quetiapine. The U.S., in particular, has a large patient population with conditions such as schizophrenia and bipolar disorder, contributing to the high market share. Additionally, the availability of both branded and generic formulations of Quetiapine Fumarate has increased accessibility and affordability, supporting continued growth in the region.

Europe

Europe accounted for around 30% of the global Quetiapine Fumarate market in 2022. The region's demand for Quetiapine is driven by the rising incidence of mental health disorders such as schizophrenia, bipolar disorder, and depression. European healthcare systems are increasingly adopting newer medications, including Quetiapine Fumarate, to treat these conditions. The availability of generic versions of Quetiapine has also made it more accessible across countries like Germany, the UK, and France. Increased awareness and improved diagnosis of mental health conditions in Europe are expected to further drive demand for Quetiapine Fumarate in the coming years.

Asia-Pacific

Asia-Pacific represents a rapidly growing market for Quetiapine Fumarate, accounting for approximately 18% of the global market in 2022. The region has seen increased recognition of mental health conditions and a growing willingness to seek treatment. Countries like Japan, China, and India have large populations, and the increasing diagnosis of schizophrenia and bipolar disorder is contributing to the rising demand for antipsychotic medications. As healthcare access improves and awareness campaigns increase in countries with developing healthcare systems, the market for Quetiapine Fumarate in Asia-Pacific is expected to expand further.

Middle East & Africa

The Middle East & Africa (MEA) region accounted for about 7% of the Quetiapine Fumarate market in 2022. The demand for antipsychotic medications in the MEA region is driven by the increasing awareness of mental health disorders, although the market is still emerging. The rise in disposable incomes and healthcare access, especially in countries like Saudi Arabia and South Africa, is improving the accessibility of medications like Quetiapine Fumarate. While the market remains relatively small compared to other regions, it is expected to grow as healthcare systems in the region continue to develop and expand mental health services.

LIST OF KEY Quetiapine Fumarate Market COMPANIES PROFILED

• Zhejiang Huahai Pharmaceutical
• Hexal
• SuZhou NO.4 Pharmaceutical Factory
• Lupin
• Intas
• Sun Pharmaceutical
• Dr. Reddy’s
• Fuan Pharmaceutical
• Hunan Dongting Pharm
• TAPI
• Zhejiang Supor Pharmaceuticals
• Accord
• AstraZeneca

Top 2 Companies with Highest Market Share

1. AstraZeneca AstraZeneca is a leading player in the Quetiapine Fumarate market, holding a market share of approximately 25%. The company manufactures the original branded version, Seroquel, which is widely prescribed for treating schizophrenia, bipolar disorder, and major depressive disorder. AstraZeneca’s strong global presence and extensive research into psychiatric treatments have solidified its position as a market leader in the Quetiapine Fumarate segment.

2. Sun Pharmaceutical Sun Pharmaceutical holds around 15% of the Quetiapine Fumarate market. As one of the largest generic pharmaceutical companies, Sun has a significant share of the market due to its generic version of Quetiapine. The company's strategic focus on affordable medications and its robust global distribution network have contributed to its strong market presence, particularly in regions like North America and Asia.

Investment Analysis and Opportunities

The Quetiapine Fumarate market offers substantial investment opportunities due to the rising global prevalence of mental health disorders and the growing acceptance of pharmacological treatments. In 2022, approximately 6.5% of the global population was affected by schizophrenia, bipolar disorder, or depression, creating a large patient pool for Quetiapine Fumarate. This trend is expected to continue as more individuals seek treatment for these conditions. The generic market for Quetiapine Fumarate has seen significant growth, accounting for approximately 55% of the total market share, driven by the expiration of the Seroquel patent and the introduction of affordable alternatives. As more patients seek effective and cost-efficient treatments, the demand for generic Quetiapine Fumarate will continue to rise. Furthermore, increasing healthcare access in developing regions like Asia-Pacific and Africa presents additional opportunities for market growth. With expanding mental health services in emerging economies, Quetiapine Fumarate’s market share is likely to increase as both branded and generic formulations become more accessible. The continuous research into new drug formulations and delivery methods, such as extended-release tablets, offers further growth prospects. Investing in companies involved in these advancements, as well as in regions where access to mental health treatments is expanding, represents a promising avenue for future returns.

NEW PRODUCTS Development

The development of new formulations of Quetiapine Fumarate is a key focus for many pharmaceutical companies. One significant trend is the growth of extended-release tablets, which accounted for around 32% of the market in 2022. These tablets provide longer-lasting therapeutic effects, which is crucial for patients requiring long-term management of conditions like bipolar disorder and schizophrenia. Sun Pharmaceutical, a major player in the generic segment, has been actively developing innovative formulations to improve patient adherence to treatment by reducing side effects like sedation, which is common with immediate-release versions. Another example of innovation is the development of combination therapies, where Quetiapine Fumarate is being combined with other medications to enhance its effectiveness in treating major depressive disorder. Additionally, ongoing research into patient-centric formulations, such as dissolvable tablets or liquid forms, is expanding the market's potential by improving accessibility for patients who may have difficulty swallowing traditional tablets. The growing focus on personalized medicine, which tailors treatments based on individual needs, is expected to result in more precise and effective Quetiapine Fumarate products. These innovations are driving the market’s expansion and are expected to contribute to significant growth in the coming years.

Recent Developments by Manufacturers in Quetiapine Fumarate Market

• Sun Pharmaceutical launched an improved extended-release version of Quetiapine Fumarate in early 2024, which offers enhanced bioavailability and reduced sedation for patients with bipolar disorder.

• AstraZeneca announced the development of a new combination therapy in 2025, which includes Quetiapine Fumarate, designed to enhance its efficacy in the treatment of depression in patients with comorbid anxiety disorders.

• Lupin Pharmaceuticals introduced a generic version of Quetiapine Fumarate with a new tablet formulation in 2025 that improves dissolution rate, ensuring faster absorption and better patient compliance.

• Dr. Reddy’s expanded its portfolio of Quetiapine Fumarate generics in 2024, launching a new liquid form designed for pediatric and elderly populations who have difficulty with solid tablets.

• Intas Pharmaceuticals developed a Quetiapine Fumarate combination drug in 2024, aimed at improving treatment outcomes for patients with schizophrenia and major depressive disorder by reducing relapse rates.

REPORT COVERAGE of Quetiapine Fumarate Market

This report provides a comprehensive analysis of the global Quetiapine Fumarate market, including key trends, growth drivers, and competitive dynamics. It covers market segmentation by type, including immediate-release and extended-release tablets, and highlights the increasing demand for generic alternatives. The report also addresses the primary therapeutic applications, such as schizophrenia, bipolar disorder, and depression, which represent the largest portions of the market. It also provides insights into regional dynamics, showcasing the leading markets in North America, Europe, and Asia-Pacific. The report profiles key market players like Sun Pharmaceutical, AstraZeneca, and Lupin Pharmaceuticals, with a detailed focus on their strategies, product innovations, and recent developments. Additionally, the report explores investment opportunities, particularly in the expanding generic segment and emerging markets with increasing access to mental health treatments. The analysis further delves into the challenges posed by competition and side effects, as well as the opportunities created by new drug formulations and combination therapies.